Table 2.

Cellular parameters before and after Canagliflozin treatment

Parameter	Placebo (n = 14)			Canagliflozin (n = 15)			Fixed effects test P value
	Visit 1	Visit 2	Visit 3	Visit 1	Visit 2	Visit 3
Mean MNC	167.00 ± 16.08	153.79 ± 16.08	155.09 ± 16.08	147.75 ± 15.54	145.93 ± 15.54	155.09 ± 15.54	0.71
Mean CD34+ve	2527.64 ± 508.69	3128.79 ± 508.69	3157.36 ± 508.69	2452.07 ± 491.44	2031.40 ± 491.44	2682.93 ± 491.44	0.32
% of CD34+ve	1.01 ± 0.19	1.04 ± 0.17	1.23 ± 0.21	0.94 ± 0.19	0.85 ± 0.22	0.93 ± 0.17	0.75
% of CD31+ve	2.85 ± 0.33	2.47 ± 0.44	2.16 ± 0.43	2.75 ± 0.33	2.34 ± 0.38	2.58 ± 0.35	0.59
CD34+CD184	0.57 ± 0.09	0.45 ± 0.10	0.61 ± 0.11	0.43 ± 0.09	0.33 ± 0.10	0.37 ± 0.09	0.62
CFU	10.30 ± 2.03	13.62 ± 2.10	13.61 ± 2.19	6.08 ± 1.95	7.62 ± 1.95	7.53 ± 1.89	0.82
SDF 10 NG	0.20 ± 0.031	0.20 ± 0.031	0.23 ± 0.03	0.15 ± 0.03	0.15 ± 0.03	0.26 ± 0.03	0.26
SOD2	0.97 ± 0.23	1.45 ± 0.23	0.92 ± 0.24	1.00 ± 0.22	1.05 ± 0.24	1.36 ± 0.24	0.22
Catalase	− 0.03 ± 0.25	− 0.09 ± 0.25	− 0.61 ± 0.26	− 0.55 ± 0.23	− 0.55 ± 0.26	0.20 ± 0.26	0.04
GPX35	2.00 ± 0.54	2.00 ± 0.54	1.71 ± 0.54	2.00 ± 0.47	1.64 ± 0.50	2.25 ± 0.54	0.68
CXCL12	1.00 ± 0.16	0.53 ± 0.17	0.33 ± 0.17	1.00 ± 0.15	0.60 ± 0.16	0.63 ± 0.18	0.59
CXCR4	1.06 ± 0.17	1.03 ± 0.17	0.90 ± 0.18	1.00 ± 0.16	1.03 ± 0.18	1.58 ± 0.18	0.06
EDN1	1.22 ± 0.27	1.05 ± 0.29	1.03 ± 0.29	1.00 ± 0.24	0.79 ± 0.27	2.10 ± 0.27	0.02
VEGEF-A	0.95 ± 0.17	1.46 ± 0.18	0.83 ± 0.19	1.00 ± 0.17	0.86 ± 0.18	1.12 ± 0.19	0.04
PECAM	0.94 ± 0.11	1.43 ± 0.11	0.89 ± 0.12	1.00 ± 0.11	0.87 ± 0.12	1.28 ± 0.12	0.002
KDR	1.00 ± 0.18	0.53 ± 0.18	0.50 ± 0.20	1.00 ± 0.18	0.55 ± 0.20	1.16 ± 0.20	0.13
NOS3	1.11 ± 0.21	0.06 ± 0.21	− 0.25 ± 0.21	0 ± 0.18	− 0.23 ± 0.19	0.34 ± 0.21	0.08
Wilm’s tumor	6.52 ± 0.65	6.13 ± 0.72	6.36 ± 0.75	6.27 ± 0.60	6.68 ± 0.62	5.75 ± 0.59	0.45
Nephrin	6.15 ± 0.55	5.10 ± 0.62	5.87 ± 0.65	5.39 ± 0.51	5.70 ± 0.53	5.24 ± 0.50	0.25
PODXL	6.72 ± 0.33	6.08 ± 0.38	6.68 ± 0.40	7.05 ± 0.31	6.92 ± 0.32	6.62 ± 0.30	0.34